The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...

Targeted protein degradation is a therapeutic strategy that utilizes the cell’s natural machinery to eliminate disease-causing proteins. The field traces its origins to the development of thalidomide ...

Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier.

Genentech, a division of Roche, will pay China’s Jemincare $60 million up front in a deal to develop a prostate cancer treatment that is based on targeted protein degradation. Proteolysis-targeting ...

Co. Ltd. have disclosed proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to a Bruton tyrosine kinase (BTK)-targeting moiety. They are ...

Daiichi Sankyo is the winner in the latest antibody-drug conjugate patent battle against Seagen. Roche is buying a prostate cancer protein degrader from a Chinese company. AbbVie has pulled the plug ...